A relevant scientific study by BCI and authored by Filippo Naso, Alessandro Gandaglia, Giulio Sturaro, Cesare Galli, and Robert J. Melder has just been published in Frontiers in Bioscience-Landmark journal to further validate the scientific basis of BCI’s technology for ensuring the long-lasting biocompatibility of implantable biological tissues. The study, titled “The α-Gal KO Mouse […]
Read
In the interview realized by Roberto Poletti for Rai IsoRadio, Alessandro Gandaglia (CEO of BCI) explains how his company was born and how they realized a new and innovative technology completely ‘made in Italy’. The product developed by BCI (Biocompatibility Innovation) is unique, with an impressive potential to improve patients’ life and contribute to reducing […]
Read
A clear and complete explanation of the FACTA Technology emerged within the interview realized by TelePadova to Alessandro Gandaglia (CEO of BCI).
Read
In the interview with Caffè Europa, on Rai Radio 1, Alessandro Gandaglia, biologist and co-founder, together with Filippo Naso and Ugo Stefanelli, of BCI (BioCompatibility Innovation), explains the functioning of the “Facta” protocol that exploits the action of naturally derived active ingredients capable of doubling the duration of heart valves of animal origin.
Read
The Italian startup BCI – BioCompatibility has developed a new technology which is able to double the duration of biological heart valves thanks to the implementation of naturally derived active ingredients. The financing strongly contributed to the implementation of the project: «We achieved the results thanks to who believed in us and financed the project, […]
Read
A Made in Italy technology that allows the doubling of the life of biological heart valves. The solution was developed by BCI, the innovative company led by Alessandro Gandaglia, Filippo Naso and Ugo Stefanelli. The team of researchers developed the Facta method, a patent on which the attention of large American and Chinese companies that […]
Read
«Our company BCI has entered into negotiations with the two main industrial partners in the field of biological heart valves – in terms of sales volume» declared Alessandro Gandaglia, CEO of BCI to Fortune. The greatest benefits of the FACTA Technology developed by BCI are the reduction by 20-30% of the valve replacement surgeries and its […]
Read
Eighty-five highly specialized ventures including companies, research centers, and trade associations. Over 70 valued patents. A community where cross-contamination of ideas generates new business projects. A great environment for BCI – Biocompatibility Innovation, which became part of Unismart since May 2020. Unismart is the Foundation of the University of Padua, born to promote the technology […]
Read
May 2019. BCI, BioCompatibility Innovation, is among the first innovative startups selected to be part of G-Factor, the new space of the Golinelli Foundation, inaugurated last February in Bologna. The Padua-based startup joins the elite group of nine startups and one competence center, the first “tenants” of the five thousand square meters of the new […]
Read
My name is Alessandro Gandaglia and I’m the CEO of Biocompatibility Innovation. This video is in Italian, performed in 2018 as a testimonial for the Business School I attended, 8 years after I got my MBA. I describe myself and the professional experience that led me to pursue a new life as an entrepreneur.
Read
July 2018. Months of work, day and night, thanks to the intervention of an excellent team – cardio surgeons and veterinarians – at the Gemelli University Hospital in Rome. And the initial results confirm the validity of the treatment developed by BCI (BioCompatibility Innovation), the innovative startup from Padua that utilizes the action of naturally […]
Read
July 2017. An innovative treatment to double the lifespan of animal-derived cardiac valve substitutes. This is what BCI, BioCompatibility Innovation, an innovative startup based in Padua, is developing. It involves two biologists with academic experience and has already secured €700,000 in funding. In September, the first official trial will begin in collaboration with the Policlinico […]
Read